If you are managing dyslipidemia, you may hear the term very high risk in cholesterol care. This label is used in clinical ASCVD prevention to identify people who have a greater chance of future cardiovascular events and may need closer attention to LDL-C lowering.

In simple terms, very high risk is not a cholesterol number by itself. It is a risk category based on a person’s ASCVD history and certain high-risk features.

What does “very high risk” mean?

Clinical ASCVD includes a history of:

• Acute coronary syndromes
• Myocardial infarction
• Stable or unstable angina
• Coronary or other arterial revascularization
• Stroke
• Transient ischemic attack
• Peripheral artery disease

Within that group, very high risk is defined in two main ways:

1) Multiple major ASCVD events

This includes a history of multiple major ASCVD events such as:

• Acute coronary syndrome within the past 12 months
• History of myocardial infarction
• History of ischemic stroke
• Symptomatic peripheral artery disease

2) One major ASCVD event plus multiple high-risk conditions

A person may also be considered very high risk if they have one major ASCVD event and multiple high-risk conditions. High-risk conditions listed in the guideline include:

• Age over 65 years
• Coronary artery revascularization
• Current smoker
• Diabetes
• History of heart failure
• Hypertension
• LDL-C greater than 100 mg/dL despite maximally tolerated statin plus ezetimibe

Why this category matters

Very high risk matters because it helps guide how aggressively LDL-C should be addressed in secondary prevention. The goal is to match the intensity of care to the level of risk.

For people with ASCVD, statins are described as first-line therapy for ASCVD risk reduction in nearly all patients. More intensive statin therapy has also been associated with additional reduction in major vascular events compared with less intensive therapy.

How clinicians think about risk in practice

A very high risk label is usually based on a combination of:

• Past cardiovascular events
• Current risk features
• LDL-C response to treatment

This is why a complete review of history matters. A person with prior ASCVD may move into a very high risk category if they have repeated events or if they have one major event plus several high-risk conditions.

What information is typically reviewed?

When cholesterol care is being assessed, the following details are especially relevant:

• History of ACS, MI, stroke, TIA, PAD, or revascularization
• Whether an event happened recently, especially within the past 12 months
• Age
• Smoking status
• Presence of hypertension
• History of heart failure
• Diabetes status
• LDL-C level despite treatment
• Whether statin and ezetimibe therapy has already been maximized

This structured review helps clarify whether someone fits a very high risk pattern.

What treatment themes are supported?

The guideline material supports a stepwise LDL-C lowering approach in ASCVD care.

Statins

Statins are oral agents that competitively inhibit HMG-CoA reductase, the rate-limiting step of endogenous cholesterol production. They also increase LDL receptor expression on hepatocytes.

Commonly listed statin therapy includes atorvastatin, with a typical dose range of 10 to 80 mg once daily.

Ezetimibe and other LDL-C lowering options

The very high risk definition specifically mentions LDL-C greater than 100 mg/dL despite maximally tolerated statin plus ezetimibe as one of the high-risk conditions.

Other LDL-C lowering medications may also be considered in ASCVD care, but the key point is that treatment decisions are tied to the person’s risk category and LDL-C response.

A practical way to understand the label

You can think of very high risk as a signal that:

• The person has established ASCVD
• The person has had more than one major event, or one major event plus several high-risk features
• LDL-C lowering should be reviewed carefully
• Treatment intensity may need to be higher than in lower-risk situations

This is a clinical classification, not a personal failure. It is used to organize care and reduce future risk.

Questions to ask your care team

If you have been told you are at very high risk, useful questions include:

• Which ASCVD events or risk features place me in this category?
• Is my LDL-C still above target despite current treatment?
• Have statin and ezetimibe therapy been maximized?
• What follow-up is needed to review my response?
• How do my other risk factors, such as hypertension or smoking, affect my overall risk?

Integrative Ayurveda and total health perspective

In an Integrative Ayurveda and Total Health framework, cholesterol care is best viewed as part of the whole person. The Connectome of Health model emphasizes balance across mind, body, and environment and their interrelationships.

That means a very high risk label should be understood in a broader health context:

• Body: cardiovascular history, LDL-C response, and other risk conditions
• Mind: awareness, adherence, and readiness to engage in care
• Environment: daily routines, support systems, and follow-up structure

This holistic view does not replace clinical risk assessment. Instead, it supports a more complete and organized approach to care.

Key takeaways

• Very high risk is a cholesterol care category used in ASCVD prevention.
• It applies to people with multiple major ASCVD events, or one major event plus multiple high-risk conditions.
• High-risk conditions include age over 65, smoking, hypertension, diabetes, heart failure, revascularization, and LDL-C above 100 mg/dL despite maximally tolerated statin plus ezetimibe.
• Statins are first-line therapy for ASCVD risk reduction in nearly all patients.
• A whole-health approach can support better understanding, follow-up, and long-term care.

Conclusion

Very high risk in cholesterol care means the person has established ASCVD with a pattern of repeated events or added high-risk features. The label helps clinicians focus on LDL-C lowering and secondary prevention in a structured way. If you are reviewing your own care, the most useful next step is to understand which events and risk factors place you in this category and how your current treatment is working.